

Date: 14.02.2023

To,

Department of Corporate Services Bombay Stock Exchange Limited Floor 25, PJ Towers Dalal Street, Mumbai – 400 001	National Stock Exchange of India Ltd Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai 400 051
---	--

Dear Sir,

Sub: Outcome of the Board Meeting held on 14.02.2023

Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, this is to inform you that the Board of Directors in their just concluded Board meeting held today have:

- Considered and adopted the Un-audited financial results of the Company for the quarter / nine months ended 31.12.2022;

In this connection find attached the following:

1. Copy of Un-audited financial results of the Company for the quarter / nine months ended 31.12.2022 alongwith Limited Review Report

The meeting commenced at 4.00 PM and ended at 4:30 PM.

This is for your information and records.

Thanking you
Yours truly

For Celestial Biolabs Limited

NAGA

LATHA SADA

Digitally signed by
NAGA LATHA SADA
Date: 2023.02.14
16:34:36 +05'30'

Sada Naga Latha
Compliance officer & Company Secretary
M No. ACS 59897

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIIIC Tech Park, IDA Nacharam, Hyderabad-500 076
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec, 2022


SL.NO.	PARTICULARS	Rs In lacs					
		Quarter Ended			Nine month period ended		Year Ended
		31.12.2022 (Unaudited)	30.09.2022 (Unaudited)	31.12.2021 (Unaudited)	31.12.2022 (Unaudited)	31.12.2021 (Unaudited)	31.03.2022 (Audited)
I	a) Revenue from operations						
II	b) Other Income	3.38	4.18	3.62	13.07	8.43	14.75
III	Total income (I+II)	-	-	-	-	-	-
IV	Expenditure	3.38	4.18	3.62	13.07	8.43	14.75
	a) Cost of raw and packing materials consumed						
	b) Purchase of Traded Products	2.15	2.51	2.44	8.02	5.02	8.92
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	-	-	-	-	-	-
	d) Employee Benefits Expense	-	-	-	-	-	-
	e) Depreciation and amortization	5.15	4.53	3.68	13.86	8.05	12.32
	f) Finance Cost	0.70	0.70	0.72	2.10	2.32	3.02
	g) Other Expenses	0.07	0.07	-	0.22	-	0.07
	Total expenses	10.58	4.56	1.53	22.47	6.47	31.36
V	Profit / (Loss) before exceptional items and Tax (III-IV)	18.64	12.38	8.38	46.67	21.86	55.70
VI	Exceptional items	(15.26)	(8.20)	(4.76)	(33.60)	(13.43)	(40.95)
VII	Profit / (Loss) before tax (V-VI)	-	-	-	-	-	-
VIII	Tax expense	(15.26)	(8.20)	(4.76)	(33.60)	(13.43)	(40.95)
IX	Net Profit / (Loss) for the period (VII-VIII)	-	-	-	-	-	-
X	Other Comprehensive Income,	(15.26)	(8.20)	(4.76)	(33.60)	(13.43)	(40.95)
	Total Other Comprehensive Income, net of Tax	-	-	-	-	-	-
XI	Total Comprehensive Income for the period	(15.26)	(8.20)	(4.76)	(33.60)	(13.43)	(40.95)
XII	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63	2,258.63
XIII	Earning Per Share for the Period						
	Basic	(0.07)	(0.04)	(0.02)	(0.15)	(0.06)	(0.18)
	Diluted	(0.07)	(0.04)	(0.02)	(0.15)	(0.06)	(0.18)


Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at it's meeting held on 14.02.2023
- Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement Principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time.
- The Financial results and other financial information for the quarter ended 31st December, 2022 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any audit, it is only subject to review of statutory auditors. Results are available on the National stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) and in Company's website www.celestialbiolabs.com
- During the Financial year 2019-20 the company incurred net losses of Rs 9,834.17 lacs. Consequently, the Networth which was at 10,227.30 at the beginning of the financial year 2019-20 came down to Rs. 393.13 lakhs for year ended 31.3.2020. Also there are no sales during the financial year 2020-21. The company resumed its sales operations in the quarter ended september 2021. Significant decline in the revenue, sale of fixed assets in the earlier years and adverse financial ratios have casted a doubt on the Company's ability to continue as a going concern. The management is taking strategic and operational actions mitigating such doubt/uncertainty by engaging in settlement negotiations with the lenders for the borrowings outstanding and looking for strategic partnership, and applying for further renewal request for manufacture for sale of ayurveda drug licences to improve the Company's financial condition. Hence the Company has prepared these financial statements under going concern basis of preparation

HYDERABAD
Date: 14.02.2023

Managing director





LIMITED REVIEW REPORT

To,
The Board Members of
Celestial Biolabs Limited

We have reviewed the accompanying "Statement of unaudited financial results of M/s Celestial Biolabs Limited for quarter ended 31 December, 2022", and year to date results for the period from 01 April 2022 to 31 December 2022 ("The statement")

The statement, which is the responsibility of the company's management and approved by the board of directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We Conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an Audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial Results, prepared in accordance with applicable accounting standards specified under section 33 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014, and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

We draw attention to Note 4 to the Statement, which indicates that the Company certain matters indicate that a material uncertainty may exist as referred in note 4 to the statement that may cast doubt on Company's ability to continue as a going concern, management is taking strategic and operational actions mitigating such doubt/uncertainty.

Our conclusion is not modified in respect of this matter

Place : Hyderabad
Date: 14.02.2023

For M Surendra and Associates
Chartered Accountants
Firm Reg No. 017280S

P. Shaik Shavali P
Partner

M.No. 245517

UDIN: 23245517BGXOEU4342

